China SXT Pharmaceuticals, Inc.

China SXT Pharmaceuticals, Inc. has entered into a Securities Purchase Agreement with an institutional investor for Pre-Paid Purchases of its Class A ordinary shares, totaling up to $30,000,000. An initial purchase of $3,150,000 (before OID) is expected on July 6, 2026, with proceeds designated for working capital and corporate purposes. The company also appointed Univest Securities, LLC as the exclusive placement agent for the offering.

China SXT Pharmaceuticals, Inc. entered into a sales agreement with Univest Securities, LLC on June 1, 2026, to offer and sell up to $100,000,000 of its Class A ordinary shares through an at-the-market offering. Univest Securities will act as the sales agent, earning a 3.00% commission on gross proceeds, plus a $0.003 per share trading and exchange fee reimbursement. The offering is registered under the company's existing shelf registration statement.

China SXT Pharmaceuticals, Inc. completed a securities offering on May 2, 2026, issuing Class A Ordinary Shares and Warrants. The offering generated gross proceeds of $3.5 million, with net proceeds allocated for working capital and general corporate purposes. The securities were issued in reliance on Regulation S, with purchasers confirming they were not U.S. residents or "U.S. persons."